Brian Matthew Zeglis

Hunter College of the City University of New York, New York, NY, United States 
Radiopharmaceutical Chemistry
"Brian Zeglis"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Sarrett SM, Rodriguez C, Delaney S, et al. (2024) Evaluating CD133 as a Radiotheranostic Target in Small-Cell Lung Cancer. Molecular Pharmaceutics
Yeh R, O'Donoghue JA, Jayaprakasam VS, et al. (2024) First-in-Human Evaluation of Site-Specifically Labeled Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
Bauer D, Cornejo MA, Hoang TT, et al. (2023) Click Chemistry and Radiochemistry: An Update. Bioconjugate Chemistry
Delaney S, Rodriguez C, Sarrett SM, et al. (2023) Unraveling the in vivo fate of inhaled micro- and nanoplastics with PET imaging. The Science of the Total Environment. 904: 166320
Delaney S, Sebastiano J, Zeglis BM, et al. (2023) Molecular Imaging, Radiochemistry, and Environmental Pollutants. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
Keinänen O, Sarrett SM, Delaney S, et al. (2023) Visualizing Galectin-3 Binding Protein Expression with ImmunoPET. Molecular Pharmaceutics
Bauer D, Sarrett SM, Lewis JS, et al. (2023) Click chemistry: a transformative technology in nuclear medicine. Nature Protocols
Zeglis BM, Lewis JS. (2022) Click Here for Better Chemistry. The New England Journal of Medicine
MacPherson DS, Hwang D, Sarrett SM, et al. (2022) Leveraging a Dual Variable Domain Immunoglobulin to Create a Site-Specifically Modified Radioimmunoconjugate. Molecular Pharmaceutics
Feng Y, Sarrett SM, Meshaw RL, et al. (2022) Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent. Journal of Medicinal Chemistry
See more...